May Bacterial Infections Trigger Bullous Pemphigoid? Case Report and Review of Literature
Abstract
:1. Introduction
2. Case Report
3. Discussion
4. Conclusions
5. Ethic Statement
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Bağcı, I.S.; Horváth, O.N.; Ruzicka, T.; Sárdy, M. Bullous pemphigoid. Autoimmun. Rev. 2017, 16, 45–455. [Google Scholar] [CrossRef]
- Di Zenzo, G.; Marazza, G.; Borradori, L. Bullous pemphigoid: Physiopathology, clinical features and management. Adv. Dermatol. 2007, 23, 257–288. [Google Scholar] [CrossRef] [PubMed]
- Schmidt, E.; Zillikens, D. Pemphigoid diseases. Lancet 2013, 381, 320–332. [Google Scholar] [CrossRef]
- Parker, S.R.; MacKelfresh, J. Autoimmune blistering diseases in the elderly. Clin. Dermatol. 2011, 29, 69–79. [Google Scholar] [CrossRef]
- Yancey, K.B. The pathophysiology of autoimmune blistering disorders. J. Clin. Investig. 2005, 115, 825–828. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sagi, L.; Baum, S.; Agmon-Levin, N.; Sherer, Y.; Katz, B.S.; Barzilai, O.; Ram, M.; Bizzaro, N.; SanMarco, M.; Trau, H.; et al. Autoimmune bullous diseases the spectrum of infectious agent antibodies and review of the literature. Autoimmun. Rev. 2011, 10, 527–535. [Google Scholar] [CrossRef]
- Marazza, G.; Pham, H.C.; Schärer, L.; Pedrazzetti, P.P.; Hunziker, T.; Trüeb, R.M.; Hohl, D.; Itin, P.; Lautenschlager, S.; Naldi, L.; et al. Autoimmune bullous disease Swiss study group. Incidence of bullous pemphigoid and pemphigus in Switzerland: A 2-year prospective study. Br. J. Dermatol. 2009, 161, 861–868. [Google Scholar] [CrossRef]
- Joly, P.; Benichou, J.; Lok, C.; Hellot, M.F.; Saiag, P.; Tancrede-Bohin, E.; Sassolas, B.; Labeille, B.; Doutre, M.S.; Gorin, I.; et al. Prediction of survival for patients with bullous pemphigoid: A prospective study. Arch. Dermatol. 2005, 141, 691–698. [Google Scholar] [CrossRef] [Green Version]
- Delgado, J.C.; Turbay, D.; Yunis, E.J.; Yunis, J.J.; Morton, E.D.; Bhol, K.; Norman, R.; Alper, C.A.; Good, R.A.; Ahmed, R. A common major histocompatibility complex class II allele HLA-DQB1* 0301 is present in clinical variants of pemphigoid. Proc. Natl. Acad. Sci. USA 1996, 93, 8569–8571. [Google Scholar] [CrossRef] [Green Version]
- Moro, F.; Fania, L.; Sinagra, J.L.M.; Salemme, A.; Zenzo, G.D. Bullous pemphigoid: Trigger and predisposing factors. Biomolecules 2020, 10, 1432. [Google Scholar] [CrossRef]
- Balestri, R.; Magnano, M.; La Placa, M.; Patrizi, A.; Angileri, L.; Tengattini, V.; Bardazzi, F. Malignancies in bullous pemphigoid: A controversial association. J. Dermatol. 2015, 43, 125–133. [Google Scholar] [CrossRef] [Green Version]
- Atzmony, L.; Mimouni, I.; Reiter, O.; Leshem, Y.A.; Taha, O.; Gdalevich, M.; Hodak, E.; Mimouni, D. Association of bullous pemphigoid with malignancy: A systematic review and meta-analysis. J. Am. Acad. Dermatol. 2017, 77, 691–699. [Google Scholar] [CrossRef] [PubMed]
- Chen, J.; Mao, X.; Zhao, W.; Zhang, B.; Chen, X.; Yu, C.; Zheng, Z.; Jin, H.; Li, L. Assessment of the characteristics and associated factors of infectious complications in bullous pemphigoid. Front. Immunol. 2020, 11, 1607. [Google Scholar] [CrossRef] [PubMed]
- Sadik, C.D.; Schmidt, E. Resolution in bullous pemphigoid. Semin. Immunopathol. 2019, 41, 645–654. [Google Scholar] [CrossRef] [Green Version]
- Dimson, O.G.; Giudice, G.J.; Fu, C.L.; Van den Bergh, F.; Warren, S.J.; Janson, M.M.; Fairley, J.A. Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid. J. Investig. Dermatol. 2003, 120, 784–788. [Google Scholar] [CrossRef] [Green Version]
- Simon, D.; Borradori, L.; Simon, H.U. Eosinophils as putative therapeutic targets in bullous pemphigoid. Exp. Dermatol. 2017, 26, 1187–1192. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Diny, N.L.; Rose, N.R.; Čiháková, D. Eosinophils in autoimmune diseases. Front. Immunol. 2017, 8, 484. [Google Scholar] [CrossRef]
- Chakievska, L.; Holtsche, M.M.; Künstner, A.; Goletz, S.; Petersen, B.S.; Thaci, D.; Ibrahim, S.M.; Ludwig, R.J.; Franke, A.; Sadik, C.D.; et al. IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. J. Autoimmun. 2019, 96, 104–112. [Google Scholar] [CrossRef]
- Murrell, D.F.; Daniel, B.S.; Joly, P.; Borradori, L.; Amagai, M.; Hashimoto, T.; Caux, F.; Marinovic, B.; Sinha, A.A.; Hertl, M.; et al. Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts. J. Am. Acad. Dermatol. 2012, 66, 479–485. [Google Scholar] [CrossRef] [Green Version]
- Hoffmann, J.H.O.; Enk, A.H. High-dose intravenous immunoglobulin in skin autoimmune disease. Front. Immunol. 2019, 10, 1090. [Google Scholar] [CrossRef] [PubMed]
- Döpp, R.; Schmidt, E.; Chimanovitch, I.; Leverkus, M.; Bröcker, E.B.; Zillikens, D. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in bullous pemphigoid: Serum levels of these immunoglobulins reflect disease activity. J. Am. Acad. Dermatol. 2000, 42, 577–583. [Google Scholar] [CrossRef] [PubMed]
- Chen, R.; Ning, G.; Zhao, M.L.; Fleming, M.G.; Diaz, L.A.; Werb, Z.; Liu, Z. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J. Clin. Investig. 2001, 108, 1151–1158. [Google Scholar] [CrossRef] [PubMed]
- Wintroub, B.U.; Mihm, M.C., Jr.; Goetzl, E.J.; Soter, N.A.; Austen, K.F. Morphologic and functional evidence for release of mast-cell products in bullous pemphigoid. N. Engl. J. Med. 1978, 298, 417–421. [Google Scholar] [CrossRef]
- Seppänen, A.O. Both bullous pemphigoid antigens are expressed in the central nervous system. Br. J. Dermatol. 2012, 166, 683–684. [Google Scholar] [CrossRef]
- Chen, Y.J.; Wu, C.Y.; Lin, M.W.; Chen, T.J.; Liao, K.K.; Chen, Y.C.; Hwang, C.Y.; Chu, S.Y.; Chen, C.C.; Lee, D.D.; et al. Comorbidity profiles among patients with bullous pemphigoid: A nationwide population-based study. Br. J. Dermatol. 2011, 165, 593–599. [Google Scholar] [CrossRef]
- Belgnaoui, F.; Idrissi, M.; Benyoussef, K.; Loudiye, T.; Bella, A.; Senouci, K.; Aouni, M.; Mansouri, F.; Heid, E.; Hassam, B. Idiopathic hypereosinophilic syndrome and bullous pemphigoid. Ann. Dermatol. Venereol. 2002, 129, 1291–1294. [Google Scholar] [PubMed]
- Lee, J.J.; Downham, T.F., II. Furosemide-induced bullous pemphigoid: Case report and review of literature. J. Drugs Dermatol. 2006, 5, 562–564. [Google Scholar]
- Koch, C.A.; Mazzaferri, E.L.; Larry, J.A.; Fanning, T.S. Bullous pemphigoid after treatment with furosemide. Cutis 1996, 58, 340–344. [Google Scholar] [PubMed]
- Skandalis, K.; Spirova, M.; Gaitanis, G.; Tsartsarakis, A.; Bassukas, I.D. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J. Eur. Acad. Dermatol. Venereol. 2012, 26, 249–253. [Google Scholar] [CrossRef]
- Walmsley, N.; Hampton, P. Bullous pemphigoid triggered by swine flu vaccination: Case report and review of vaccine triggered pemphigoid. J. Dermatol. Case Rep. 2011, 5, 74–76. [Google Scholar] [CrossRef] [Green Version]
- Takeichi, S.; Kubo, Y.; Arase, S.; Hashimoto, T.; Ansai, D. Brunsting-Perry type localized bullous pemphigoid, possibly induced by furosemide administration and sun exposure. Eur. J. Dermatol. 2009, 19, 500–503. [Google Scholar] [CrossRef] [PubMed]
- Panayiotou, B.N.; Prasad, M.V.; Zaman, M.N. Furosemide-induced bullous pemphigoid. Br. J. Clin. Pract. 1997, 51, 49–50. [Google Scholar]
- Tasanen, K.; Varpuluoma, O.; Nishie, W. Dipeptidyl Peptidase-4 inhibitor-associated bullous pemphigoid. Front. Immunol. 2019, 10, 1238. [Google Scholar] [CrossRef] [Green Version]
- Bach, J.F. Infections and autoimmune diseases. J. Autoimmun. 2005, 25, 74–80. [Google Scholar] [CrossRef]
- Drago, F.; Nozza, P.; Casazza, S.; Brusati, C.; Bandelloni, R.; Rebora, A. Human herpesviruses in bullous pemphigoid lesions. Br. J. Dermatol. 2005, 152, 375–376. [Google Scholar] [CrossRef]
- Blazsek, A.; Silló, P.; Ishii, N.; Gergerly, P., Jr.; Poor, G.; Preisz, K.; Hashimoto, T.; Medvecz, M.; Karpati, S. Searching for foreign antigens as possible triggering factors of autoimmunity: Torque Teno virus DNA prevalence is elevated in sera of patients with bullous pemphigoid. Exp. Dermatol. 2008, 17, 446–454. [Google Scholar] [CrossRef]
- Min, M.; Damstetter, E.; Chen, A.Y.-Y. Autoimmune blistering disorders in the setting of human immunodeficiency virus infection. Int. J. Women’s Dermatol. 2018, 4, 159–165. [Google Scholar] [CrossRef] [PubMed]
- De, D.; Kanwar, A.J.; Radotra, B.D.; Narang, T. Bullous eruption in a patient infected with the human immunodeficiency virus. Skinmed 2008, 7, 98–101. [Google Scholar] [CrossRef]
- Bull, R.; Fallowfield, M.; Marsden, R. Autoimmune blistering diseases associated with HIV infection. Clin. Exp. Dermatol. 1994, 19, 47–50. [Google Scholar] [CrossRef] [PubMed]
- Jang, H.; Jin, Y.-J.; Yoon, C.H.; Kim, C.-W.; Kim, L. Bullous pemphigoid associated with chronic hepatitis C virus infection in a hepatitis B virus endemic area: A case report. Medicine 2018, 97, e0377. [Google Scholar] [CrossRef]
- Batts, A.F.; Jalalat, S.Z.; Hunter-Ellul, L.; Wilkerson, M.G. Exacerbation of bullous pemphigoid after hand, foot, and mouth disease treated with rituximab. JAAD Case Rep. 2016, 2, 7–9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Löffel, F.B.; Stücker, M. Localized bullous pemphigoid triggered by erysipelas. Hautarzt 2016, 67, 829–832. [Google Scholar] [CrossRef]
- Bornhövd, E.; Partscht, K.; Flaig, M.J.; Messer, G. Bullöse Skabies und durch Skabiesbefall getriggertes bullöses Pemphigoid [Bullous scabies and scabies-triggered bullous pemphigoid]. Hautarzt 2001, 52, 56–61. [Google Scholar] [CrossRef]
- Castle, S.C.; Uyemura, K.; Fulop, T.; Makinodan, T. Host resistance and immune responses in advanced age. Clin. Geriatr. Med. 2007, 23, 463–479. [Google Scholar] [CrossRef] [PubMed]
- Chinen, J.; Shearer, W.T. Secondary immunodeficiencies, including HIV infection. J. Allergy Clin. Immunol. 2010, 125 (Suppl. 2), S195–S203. [Google Scholar] [CrossRef]
- Salemi, S.; D’Amelio, R. Could autoimmunity be induced by vaccination? Int. Rev. Immunol. 2010, 29, 247–269. [Google Scholar] [CrossRef]
- Amagai, M.; Ikeda, S.; Hashimoto, T.; Mizuashi, M.; Fujisawa, A.; Ihn, H.; Matsuzaki, Y.; Ohtsuka, M.; Fujiwara, H.; Furuta, J.; et al. A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid. J. Dermatol. Sci. 2017, 85, 77–84. [Google Scholar] [CrossRef]
- Brown, M.A.; Hatfield, J.K. Mast cells are important modifiers of autoimmune disease: With so much evidence, why is there still controversy? Front. Immunol. 2012, 3, 147. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ren, Z.; Narla, S.; Hsu, D.Y.; Silverberg, J.I. Association of serious infections with pemphigus and pemphigoid: Analysis of the Nationwide Inpatient Sample. J. Eur. Acad. Dermatol. Venereol. 2018, 32, 1768–1776. [Google Scholar] [CrossRef] [PubMed]
- Germano, V.; Cattaruzza, M.S.; Osborn, J.; Tarantino, A.; Di Rosa, R.; Salemi, S.; D’Amelio, R. Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-α antagonists. J. Transl. Med. 2014, 12, 77. [Google Scholar] [CrossRef] [Green Version]
Admission | Discharge |
---|---|
Clinical conditions
| Clinical Conditions
|
Cultures
| Cultures
|
Allergy
| Allergy
|
Autoimmunity
| Autoimmunity
|
Laboratory tests
| Laboratory tests
|
Biopsy perilesional skin
| Biopsy perilesional skin
|
Treatment
| Treatment
|
Microorganisms/Infections | Clinical | Cultural | Microscopic/Molecular | Serological | References |
---|---|---|---|---|---|
CMV-EBV-HHV6-HHV8 | x | x | [6,35] | ||
Torque Teno virus | x | [36] | |||
HIV | x | [37,38,39] | |||
HBV | x | [6] | |||
HCV | x | [40] | |||
Coxsakievirus A6 | x | [41] | |||
Helicobacter pylori | x | [6] | |||
Erysipelas | x | [42] | |||
Toxoplasma gondii | x | [6] | |||
Sarcoptes scabiei | x | x | [43] | ||
Staphylococcus aureus | Blood | This case | |||
Enterococcus faecalis | Blister fluid | This case |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Biondo, M.I.; Fiorentino, C.; Persechino, S.; Tammaro, A.; Koverech, A.; Bartolazzi, A.; Raffa, S.; Canzoni, M.; Picchianti-Diamanti, A.; Di Rosa, R.; et al. May Bacterial Infections Trigger Bullous Pemphigoid? Case Report and Review of Literature. Microorganisms 2021, 9, 1235. https://doi.org/10.3390/microorganisms9061235
Biondo MI, Fiorentino C, Persechino S, Tammaro A, Koverech A, Bartolazzi A, Raffa S, Canzoni M, Picchianti-Diamanti A, Di Rosa R, et al. May Bacterial Infections Trigger Bullous Pemphigoid? Case Report and Review of Literature. Microorganisms. 2021; 9(6):1235. https://doi.org/10.3390/microorganisms9061235
Chicago/Turabian StyleBiondo, Michela Ileen, Chiara Fiorentino, Severino Persechino, Antonella Tammaro, Angela Koverech, Armando Bartolazzi, Salvatore Raffa, Marco Canzoni, Andrea Picchianti-Diamanti, Roberta Di Rosa, and et al. 2021. "May Bacterial Infections Trigger Bullous Pemphigoid? Case Report and Review of Literature" Microorganisms 9, no. 6: 1235. https://doi.org/10.3390/microorganisms9061235
APA StyleBiondo, M. I., Fiorentino, C., Persechino, S., Tammaro, A., Koverech, A., Bartolazzi, A., Raffa, S., Canzoni, M., Picchianti-Diamanti, A., Di Rosa, R., Di Zenzo, G., Scala, E., Meneguzzi, G., Ferlito, C., Markovic, M., Caporuscio, S., Sorgi, M. L., Salemi, S., & Laganà, B. (2021). May Bacterial Infections Trigger Bullous Pemphigoid? Case Report and Review of Literature. Microorganisms, 9(6), 1235. https://doi.org/10.3390/microorganisms9061235